Amprius Technologies (NYSE: AMPX) spent last week drifting lower, closing at $9.62, down $0.20 and 2.04% for the week. Then Monday happened. The silicon anode battery maker landed a grant worth up to $75 million from the U.S. Department of War, and shares jumped roughly 10% to 11% in premarket trading, changing hands near $10.60 to $10.70. That single headline reframed the entire near-term Amprius Technologies stock forecast, and it’s the reason AMPX is trending across trading desks this morning.
This is the full breakdown: the news, the numbers, the technical levels for the week ahead, and the honest bull and bear case on a stock that Wall Street rates a Strong Buy while the charts call a Sell.
AMPX at a Glance:
| Metric | Value |
|---|---|
| Last Close (Friday, Sept. 25) | $9.62 (down $0.20, -2.04% for the week) |
| Monday Premarket Move | +10% to +11%, trading near $10.60–$10.70 |
| 52-Week High / Low | $24.23 / $6.66 |
| Market Cap | ~$1.4 billion |
| Shares Outstanding | 146.08 million |
| Consensus Rating | Strong Buy (13 Buy, 0 Hold, 0 Sell) |
| Average 12-Month Price Target | $23.00–$23.71 |
Amprius Technologies Stock Price Today: The Full Data Table
Trading and Valuation Snapshot:
| Metric | Value |
|---|---|
| Ticker / Exchange | AMPX / NYSE |
| Sector / Industry | Electrical Equipment & Parts — Silicon Anode Batteries |
| Friday’s Close | $9.62 |
| Weekly Range | Roughly $9.62–$10.02 |
| 52-Week High / Low | $24.23 / $6.66 |
| Beta | 2.35 (high volatility relative to the market) |
| Market Cap | ~$1.4 billion |
| Revenue (TTM) | $109.23 million, up 143.6% |
| Net Income (TTM) | -$38.40 million |
| EPS (TTM) | -$0.28 |
| Cash on Hand (June 30) | $74.5 million |
| Short Interest | Roughly 16.5%–19.5% of float |
| Technical Score (StockInvest.us, Sept. 25) | -3.61, a Sell Candidate rating |
Latest Reported Quarter (Q2 2026):
| Metric | Value |
|---|---|
| Q2 Revenue | $34.0 million, up 126% YoY, up 19% sequentially |
| Gross Margin | 27% |
| Raised FY2026 Revenue Guidance | At least $140 million (from $130 million) |
| Raised FY2026 Gross Margin Guidance | At least 28% (from 25%) |
| FY2026 Net Loss Guidance | Under $10 million |
| FY2026 Adjusted EBITDA Guidance | At least $4.0 million |
| Key Q2 Win | Multi-year Stark Future supply deal worth over $100 million |
| Other Q2 Win | $24.0 million order from a major European drone developer |
The revenue trajectory is the backbone of every bullish argument on this stock, and the guidance raise is real, not aspirational chatter.
Why Amprius Technologies Stock Is Moving Today: The $75 Million Drone Battery Deal
Amprius secured funding of up to $75 million from the U.S. Department of War’s Industrial Base Analysis and Sustainment program. The money retrofits an existing electric vehicle battery production line, operated by a South Korean manufacturer, into a facility built to churn out high-energy-density pouch cells for unmanned aerial systems. The renovated plant targets completion in early 2028, with annual output reaching 12 million battery cells for Group 1, 2 and 3 military drones.
This isn’t Amprius’s first defense contract. The company has been steadily building a military and drone customer base alongside its commercial silicon anode business, and this grant plugs directly into that strategy: converting idle EV capacity into defense-grade manufacturing without building a new plant from scratch.
The stock’s reaction — a 10% to 11% premarket pop — is a textbook response to a government-funded capacity expansion for a small-cap that’s been trading well off its highs. It’s the kind of headline that changes a stock’s near-term setup overnight.
Beyond today’s news, three other developments have shaped sentiment over the past two months:
- Fremont facility lease extended through 2034, locking in Amprius’s core manufacturing footprint for the next decade.
- Warrant exchange agreements with institutional investors, aimed at simplifying the capital structure — a move that can reduce future dilution overhang if executed cleanly.
- A short seller report from Manatee Research leveled misconduct allegations against the company, briefly pressuring shares. Management has continued operating and reporting through the criticism, and the stock has since recovered a portion of that decline, though the report remains a live risk factor some investors still cite.
AMPX Stock Technical Analysis: Levels to Watch This Week
Coming into Monday, the technical picture on Amprius was genuinely rough. StockInvest.us rated the stock a Sell Candidate with a -3.61 technical score as of Friday’s close, noting the Sell signal has been active since August 17 and the stock had fallen nearly 16% since that signal triggered. AMPX was also trading below its 200-day simple moving average heading into today.
Today’s grant-driven surge is the first real test of whether that downtrend breaks.
| Level Type | Price | Basis |
|---|---|---|
| Major Resistance | $24.23 | 52-week high |
| Resistance 3 | $16.85 | GuruFocus GF Value fair-value estimate |
| Resistance 2 | $12.00 | Psychological round number, prior consolidation zone |
| Resistance 1 | $10.70 | Monday’s premarket high |
| Pivot / Breakout Level | $10.02 | Recent weekly high |
| Support 1 | $9.62 | Friday’s close, now first support after the gap higher |
| Support 2 | $9.00 | Round-number psychological support |
| Support 3 | $7.71–$7.72 | Recent multi-month low zone |
| Major Support | $6.66 | 52-week low |
What breaks the downtrend: a daily close above $10.70 that holds through the next session would mark the first higher-high since the August 17 sell signal began. A retreat back below $9.62 by Tuesday’s close, on the other hand, would suggest today’s pop is a one-day news bounce rather than a genuine trend reversal — exactly the pattern that’s played out with several of Amprius’s prior contract-driven rallies this year.
Volume matters here. Watch whether Monday’s volume clears the stock’s recent average; a grant-driven pop on thin volume tends to fade faster than one confirmed by heavy institutional participation.
Amprius Technologies Stock Forecast: What Wall Street Actually Says
| Firm | Analyst | Rating | Price Target | Implied Upside from $9.62 |
|---|---|---|---|---|
| Roth MKM | Chip Moore | Buy | $22 | +128.7% |
| Oppenheimer | Colin Rusch | Buy | $22 | +128.7% |
| B. Riley Securities | Ryan Pfingst | Buy | $22 | +128.7% |
| Clear Street | — | Buy | $33 | +243.0% |
| Cantor Fitzgerald | Derek Soderberg | Buy | $20 | +107.9% |
| H.C. Wainwright | Amit Dayal | Buy | $18 | +87.1% |
Ten to thirteen analysts, depending on which tracker you check, currently cover Amprius, and every single one of them carries a Buy or Strong Buy rating. Zero Hold ratings. Zero Sell ratings. The average 12-month target sits between $23 and $23.71, implying upside of well over 100% from Friday’s close.
That’s an unusually one-sided Street for a stock the technical models are simultaneously flagging as a Sell — and it’s the central tension in this entire Amprius Technologies stock forecast.
Bull Case vs. Bear Case for AMPX Stock
The bull case
Revenue grew 126% year-over-year last quarter and management raised full-year guidance for a second straight quarter, now guiding to at least $140 million in 2026 revenue and positive adjusted EBITDA. The Stark Future deal alone represents a revenue opportunity exceeding $100 million, and today’s Pentagon grant adds a fully-funded path into military drone batteries without new capital spending. Every covering analyst rates the stock a buy, with targets averaging more than double the current price. The Fremont lease extension through 2034 locks in long-term manufacturing capacity, and the warrant exchange agreements are a genuine attempt to clean up the balance sheet rather than kick dilution further down the road.
The bear case
The stock has been in a confirmed technical downtrend since mid-August, and today’s pop hasn’t yet proven it can hold. Short interest remains elevated in the high-teens as a percentage of float, meaning a meaningful slice of the market is actively betting against the stock even after the grant news. Amprius remains unprofitable, with a trailing twelve-month net loss of $38.4 million, and the Manatee Research short report raised real questions about internal practices that management hasn’t fully put to rest. Beta above 2.3 means this stock moves roughly twice as violently as the broader market in both directions — the same volatility that produces 10% rallies on good news can produce equally sharp reversals when sentiment turns.
What to Watch This Week
- Follow-through above $10.70. That’s the level that would confirm today’s move as more than a one-day news reaction.
- Volume relative to the recent average. Heavy volume on the breakout adds conviction; light volume raises the odds of a fade.
- Any update on the Manatee Research allegations. A formal company rebuttal or regulatory clearance would remove a persistent overhang; new allegations would do the opposite.
- Progress on the Fremont-to-military conversion timeline, given the 2028 completion target tied to today’s grant.
- Peer read-throughs from other defense-linked battery and drone-supply names, since government contract announcements in this space tend to lift sentiment across the group.
For a broader look at how defense-linked small caps have moved markets this year, see TruthsAndNews’ recap of the defense-earnings-driven trading session from July, which covers several names now competing with Amprius for military supply contracts.
Bottom Line
Amprius Technologies enters the week as a genuinely split story: a technically weak chart that’s been in a confirmed downtrend for six weeks, colliding head-on with a unanimous Wall Street Buy consensus and a fresh, fully-funded government contract. The $75 million grant doesn’t erase the stock’s balance sheet risk or the short seller’s lingering questions, but it does give bulls their clearest catalyst since the Stark Future deal. Whether AMPX holds above $10.70 or slides back toward $9.62 will tell you a lot about which side of that story the market believes.
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, high-beta, pre-profit stocks like Amprius Technologies carry elevated volatility risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change, sometimes significantly, within a single trading session. Support and resistance levels are derived from historical price action and are not guarantees of future performance. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
